What does Infectiology do?

Infectiology is a specialist medical practice in Ukkel. Private Limited, started on 17 November 2022, 1 establishment.

What is the address of Infectiology?

The registered office of Infectiology is located at Brugmannlaan 266, 1180 Ukkel.

Is Infectiology still active?

Yes. According to the CBE (29 October 2026) Infectiology is active, legal situation “Normale toestand”, started on 17 November 2022.

Is Infectiology registered on Peppol?

Yes, Infectiology is registered on the Peppol network with ID 0208:0793688939.

What is the enterprise number of Infectiology?

The enterprise number of Infectiology is BE0793688939.

When was Infectiology founded?

Infectiology was founded on 17 November 2022.

Who are the directors of Infectiology?

According to the 2025 annual accounts, the directors of Infectiology are: Frédérique JACOBS.

Is Infectiology a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 17 November 2022; 4 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did Infectiology make in 2025?

Infectiology posted a profit after taxes of € 29,050 in financial year 2025.

What is the revenue of Infectiology?

As a small company, Infectiology is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 53,853.

Infectiology (Private Limited) - Ukkel - BE0793688939

Dossier Infectiology, printed on 29 October 2026 from databakkes.be/en/0793688939/infectiology. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

Infectiology from Ukkel, company number BE0793688939, closed financial year 2025 with a result of € 29,050 after tax. For that financial year Infectiology recorded a gross margin of € 53,853 and equity of € 24,473. Compared with financial year 2024, the result moved from € 48,039 to € 29,050. The company is profitable. The buffer shrank hard: equity is 80 % below last year. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on July 7, 2026.

What it is worth Shrank hard

€ 24,473

▼ 80% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 29,050

▼ 40% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 26,597

▼ 73% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 127,353 paid out

More than the year’s profit went to the shareholders; reserves fell.

People and assets in 2025

Full-time equivalents estimate The annual accounts report no full-time equivalents. A micro company with one active director is usually run by that person; this is an assumption, not a figure from the source.

≈ 1

No payroll staff. One director, so that person most likely runs the business.

Vehicles and equipment

€ 22,681

▼ 33% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 5,464

▼ 23% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 12,990

▼ 41% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 11,644 Gross margin 2022: € 11,644 First fiscal year in the series	€ 90,807 Gross margin 2023: € 90,807 ▲ € 79,163 vs 2022 (€ 11,644) Favourable step	€ 67,094 Gross margin 2024: € 67,094 ▼ 26% vs 2023 (€ 90,807) Unfavourable step	€ 53,853 Gross margin 2025: € 53,853 ▼ 20% vs 2024 (€ 67,094) Unfavourable step	▼ 20%
Profit after taxes	€ 7,646 Profit after taxes 2022: € 7,646 First fiscal year in the series	€ 64,091 Profit after taxes 2023: € 64,091 ▲ € 56,445 vs 2022 (€ 7,646) Favourable step	€ 48,039 Profit after taxes 2024: € 48,039 ▼ 25% vs 2023 (€ 64,091) Unfavourable step	€ 29,050 Profit after taxes 2025: € 29,050 ▼ 40% vs 2024 (€ 48,039) Unfavourable step	▼ 40%
Equity	€ 10,646 Equity 2022: € 10,646 First fiscal year in the series	€ 74,737 Equity 2023: € 74,737 ▲ € 64,091 vs 2022 (€ 10,646) Favourable step	€ 122,776 Equity 2024: € 122,776 ▲ 64% vs 2023 (€ 74,737) Favourable step	€ 24,473 Equity 2025: € 24,473 ▼ 80% vs 2024 (€ 122,776) Unfavourable step	▼ 80%
Total debts	€ 33,352 Total debts 2022: € 33,352 First fiscal year in the series	€ 40,821 Total debts 2023: € 40,821 ▲ 22% vs 2022 (€ 33,352) Unfavourable step	€ 32,771 Total debts 2024: € 32,771 ▼ 20% vs 2023 (€ 40,821) Favourable step	€ 63,485 Total debts 2025: € 63,485 ▲ 94% vs 2024 (€ 32,771) Unfavourable step	▲ 94%
Cash	€ 2,076 Cash 2022: € 2,076 First fiscal year in the series	€ 86,660 Cash 2023: € 86,660 ▲ € 84,584 vs 2022 (€ 2,076) Favourable step	€ 99,060 Cash 2024: € 99,060 ▲ 14% vs 2023 (€ 86,660) Favourable step	€ 26,597 Cash 2025: € 26,597 ▼ 73% vs 2024 (€ 99,060) Unfavourable step	▼ 73%
Retained profit	€ 7,646 Retained profit 2022: € 7,646 First fiscal year in the series	€ 71,737 Retained profit 2023: € 71,737 ▲ € 64,091 vs 2022 (€ 7,646) Favourable step	€ 119,776 Retained profit 2024: € 119,776 ▲ 67% vs 2023 (€ 71,737) Favourable step	€ 21,473 Retained profit 2025: € 21,473 ▼ 82% vs 2024 (€ 119,776) Unfavourable step	▼ 82%
Dividend	€ 0 Dividend 2022: € 0 First fiscal year in the series	€ 0 Dividend 2023: € 0 Unchanged (€ 0) Unchanged	€ 0 Dividend 2024: € 0 Unchanged (€ 0) Unchanged	€ 127,353 Dividend 2025: € 127,353 Unchanged (€ 0) Unchanged
Balance sheet total	€ 43,998 Balance sheet total 2022: € 43,998 First fiscal year in the series	€ 115,558 Balance sheet total 2023: € 115,558 ▲ 163% vs 2022 (€ 43,998) Unchanged	€ 155,547 Balance sheet total 2024: € 155,547 ▲ 35% vs 2023 (€ 115,558) Unchanged	€ 87,957 Balance sheet total 2025: € 87,957 ▼ 43% vs 2024 (€ 155,547) Unchanged	▼ 43%

Key figures of Infectiology, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to Infectiology?

What happened at Infectiology in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jul 7, 2026 New annual accounts for financial year 2025: profit of € 29,050 (▼ 40% vs 2024). Source: NBB ↗
Nov 17, 2022 New establishment in Genappe. KBO
2022 Frédérique JACOBS became a director. NBB
Nov 17, 2022 Start of the company according to the CBE. KBO

In short

From € 7,646 profit in 2022 to € 29,050 profit in 2025.

Paid € 44,908 in corporate taxes since 2022.

Best year ever: 2023, with € 64,091 profit.

Paid out € 127,353 in dividends to the owners in total.

Original PDFs at the National Bank ↗

Management

Frédérique JACOBS

Infectiology

Behind Infectiology is Frédérique JACOBS.

Directors

According to the 2025 annual accounts

Frédérique JACOBS

Director

since 2022

Establishments

Establishment units

Physical locations of this company

Registered office

Brugmannlaan 266

1180 Ukkel

2.339.256.453

Grand route 50

1474 Genappe

Active since 17 November 2022

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 3 companies are registered at this address.

All companies at this address →

SANTE-DIGESTION

€ 68,286 gross margin · 2025

Association des copropriétaires à Uccle, avenue Brugmann 266

MAXFACE

€ 207,583 gross margin · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0793.688.939
VAT number: BE 0793.688.939
Registered office: Brugmannlaan 266, 1180 Ukkel
Names & denominations: Infectiology
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 17 November 2022
Peppol: Active · Active since 29 Dec 2025
Activities · NACE: Activiteiten van medisch specialisten

View on CBE Public ↗ Annual accounts (NBB) ↗